B
Bull
Bull · 25%ANAB
$53.20
Scenario price
$48.770
+0.039 (+0.08%)At close
Loading chart…
- High
- 49.620
- Open
- 48.970
- VWAP
- 48.79
- Volume
- 417.20K
- Mkt Cap
- 677.50M
- Low
- 47.980
- Amount
- 20.35M
- EV/EBITDA, TTM
- 16.81
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
AI analysis of AnaptysBio, Inc. (ANAB)
BuyAnaptysBio Inc appears to be a good buy right now, trading at $48.73 with a forward P/E of 21.01, which is reasonable compared to its growth potential. The recent FDA approval of Jemperli for advanced rectal cancer could significantly enhance revenue streams, and the stock has shown a 34.69% increase over the past year. However, the company faces risks with a high debt-to-equity ratio of 2423.17%, indicating potential financial instability.
Analyst Ratings (8)
+52.00% upside
Buy
8 Buy
0 Hold
0 Sell
Current: 48.77
Low
50.00
Average
74.13
High
140.00
JPMorgan
Overweight
$60
2026-09-30
JPMorgan
2026-09-30
Price Target
$60
Overweight
TD Cowen
Buy
$70
2026-08-25
TD Cowen
2026-08-25
Price Target
$70
Buy
Leerink
Outperform
$90
2026-05-15
Leerink
2026-05-15
Price Target
$90
Outperform
UBS
Buy
$76
2026-05-13
UBS
2026-05-13
Price Target
$76
Buy
Barclays
Overweight
$75
2026-05-13
Barclays
2026-05-13
Price Target
$75
Overweight
Valuation Metrics
The current forward P/E ratio for AnaptysBio, Inc. (ANAB) is 21.01, compared to its 5-year average forward P/E of -3.35.
Alphio AI Price Scenarios for ANAB
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ANAB
Events Timeline
News
8.510-19NewsfilterFDA Approves Jemperli for Advanced Rectal Cancer Treatment
9.509-22NASDAQ.COMAnaptysBio Reports Significant Q2 Profit Growth Driven by Tax Benefits
9.505-12seekingalphaAnaptysBio Q1 Earnings Report Analysis
- 5.005-11Newsfilter
AnaptysBio Strengthens Leadership Team and Board
9.004-28PRnewswireVanda Pharmaceuticals Publishes Imsidolimab Research Findings
ANAB FAQ — answered by Alphio AI
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
AnaptysBio Inc appears to be a good buy right now, trading at $48.73 with a forward P/E of 21.01, which is reasonable compared to its growth potential. The recent FDA approval of Jemperli for advanced rectal cancer could significantly enhance revenue streams, and the stock has shown a 34.69% increase over the past year. However, the company faces risks with a high debt-to-equity ratio of 2423.17%, indicating potential financial instability.
8 analysts cover ANAB: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 74.13.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.